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Introduction
The world of sport has been confronted with a substantial number of anti-doping rule violations and associated scandals in the past 12 months. This situation was epitomized by the alleged existence of government-supported doping programs l1 . 2 l (similar to those of the former German Democratic Republid 31 but also by cases of unusual pharmacokinetics of the recently prohibited drug meldonium
14
• 51 and the inadvertent administration of doping agents. 16 • 71 1he gravitas of such cases is fuelling debate for an overhaul of the global anti-doping system. 181 The current ap proach, commonly referred to as the zero-tolerance model, has been challenged and alternatives suggested based on harm reduction princip1es 191 or the scxalled stakeholder-corporate social responsibility.l 101 In that context, the dilemma of the restoration of fairness following anti-doping rule violations has been raised,r 111
and clarification as to which impetus and incentive for athletes to dope might dominate was sought. Here, amongst other critical determinants, the system of professional sports, the influence of the athletes' entourage, the athletes' morality, perception of control, perfectionism, and financial reward were identified.r1 2 -161
Healthcare professionals readily find themselves in the midst of this area of controversy}
17
• 181 and the continuous iterations of anti-doping regulations and 'doping traps' are vital in the provi sion of the best-possible services to the athlete whilst ensuring protection of the athlete and the healthcare professional from un intentional doping offencesP 9 -231 Perpetually improving the laboratory anti-doping toolbox and expanding the knowledge of new and established doping agents and methods of doping is critical for efficient sports drug testing programs. r2 41 This includes exploiting technical innovations and uti lizing alternative test matrices potentially offering complementary information and benefits to current doping control procedures (Table 1) .c 2 51 Numerous projects in anti-doping research published over the past 12 months, which are considered in this annual banned-substance review, are related to substances and methods
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of doping as classified in the Prohibited List, established and issued annually by the World Anti-Doping Agency (WADA).c 2 61 As in previous editions, the 2016 Prohibited List included 12 clas ses of prohibited substances (50-59 plus Pl and P2) and three cat egories of proscribed methods (Ml-M3) ( Table 2 ). In comparison to its 201 S version, main modifications concerned the addition of insu lin mimetics to section 54 (Hormone and Metabolic Modulators) to account for all insulin-receptor agonists (e.g. S597) while excluding compounds such as oral antidiabetics. Moreover, meldonium was shifted from the Monitoring Program (vide infra) to the Prohibited List, classified also under S4. Identifying potential patterns of abuse concerning defined substances was pursued by means of the 2016 Monitoring Program, 12 71 which differed from its 2015 predecessor by the removal of the narcotic agents hydrocodone and tapentalol, as well as the recording of morphine/codeine ratios of in competition samples and the aforementioned change of the status of meldonium. The program thus collectively covered in competition use of the stimulants bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine, and the narcotics mitragynine and tramadol. In addition, the potential (mis)use of corticosteroids and the peroxisome proliferator-activated receptor (PPAR)o agonist telmisartan during in-and out-of-competition periods was monitored. wileyonlinelibrary.com/journal!dta 
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Motivated inter alia by the alarming spectrum and amount of seized doping agents in different countriesP 8 • 291 and the continuously growing spectrum of classifiedr 301 as well as potentialr 31 -331 doping agents, new and/or complementary sports drug testing approaches were taken into consideration and, where feasible and established, implemented (as outlined in the following sections). The approaches ranged from modified and/or improved analytical instrumentation and data-mining strategiesr 34 • 351 to alternative test matrices such as, for example, dried blood spots (DBS)/dried plasma spots (DPS), oral fluid, exhaled breath, and hair.r 2 sJ Multi-analyte test methods, predominantly based on conventional chromatographic-mass spectrometric systems, continued to be the state-of-the-art in doping controls after having undergone a transition from 'drug-class dictated' to 'instrumentationdriven' analytical assays more than a decade ago.r 36 • 371 Further, the prevalence of anti-doping rule violations as reported in recent survey studiesr 381 contributed to concerns about considerable numbers of doped athletes remaining undetected, while psychometric testing as forensic diagnostic tool for individuals is, to date, not a recommended analytical option.r 391
Non-approved substances
The central role of the adenosine monophosphate (AMP)-activated protein kinase (AMPK) in the cascade of reactions resulting in the phosphorylated and deacetylated peroxisome proliferatoractivated receptor (PPAR)y co-activator 1 a (PGC -1 a), which eventually stimulates mitochondrial biogenesis, is well established.r 401 A plethora of drug candidates aimed at enhancing the biosynthesis of the muscle cells' 'powerhouses' has been the subject of preclinical and clinical tests for various therapeutic indications/ 411 and in the light of their potential to increase skeletal muscle mitochondria, a risk of misuse of these compounds in the context of athletic performance obviously exists.r 321 Among these substances, synthetic adiponectin receptor agonists such as AdipoRon and 112254 (Figure 1 ), which were shown to activate AMP I<, counteract obesity, and enhance endurance performance in laboratory rodents/ 421 were studied concerning their metabolism using human in vitro models and rat in vivo elimination studies.r 431 Phase I and phase II metabolic products from both in vitro and in vivo experiments were investigated by means of liquid chromatography (LC) combined with high resolution/high accuracy (tandem) mass spectrometry (HRMS) and stable isotope-labelling, suggesting the formation of 4 and 5 main phase I metabolites for AdipoRon and 112254 using human liver microsomal preparations, respectively. in vivo, the presence of two of the in vitro synthesized metabolites was confirmed for each drug candidate by LC-HRMS, while for AdipoRon also glucuronide and sulphate conjugates were proposed based on deconjugation experiments. By means of the obtained data, first target analytes for routine doping controls were identified albeit confirmation and completion with future human administration studies will still be required to ensure best possible long-term detection of a potential drug misuse. 
Initial testing procedures -multi-analyte screening methods and alternative chromatographic-mass spectrometric techniques
Multi-analyte testing procedures have become indispensable in routine doping controls, and the increasing number of relevant analytes, the desire to lower detection limits for enhanced retrospectivity as well as the search for an improved comprehensiveness in steroid profile analyses has resulted in several new studies and approaches exploited in sports drug testing laboratories.
Employing conventional C-18 reversed-phase LC interfaced via electrospray ionization (ESI) to low resolution triple quadrupole (QqQ) tandem mass spectrometry (MS/MS), Cha et a/. successfully analyzed 75 steroidal plus 3 non-steroidal anabolic agents from human urine.£ 481 Following solid-phase extraction (SPE). the retained analytes were enzymatically hydrolyzed and subjected to targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS), where precursor ions represented either the protonated species of the target compounds or protonated species after elimination of one or two molecules of water. The method allowed for limits of detection (LODs) between 0.05 and 20 ng/ml and thereby illustrated the utility as well as limitations of conventional LC-ESI-MS/ MS for testing different classes of anabolic agents and their metabolites in human urine. Avoiding the need for enzymatic or chemical hydrolysis of metabolites of AAS prior to LC-MS/MS analysis has been the subject of in-depth studies lately. The approach of measuring intact phase II metabolites of AAS necessitates glucuronoand sulphoconjugated reference substances, a selection of which was prepared and employed in doping control analytical methods by Rzeppa et a/.r 491 Focusing on boldenone, trenbolone, nandrolone, metenolone, and drostanolone, sulphoconjugates of the drugs and relevant phase I metabolites were produced and a test method based on SPE and LC-MS/MS was established. Following the extraction of 0.5 ml of urine on a mixed-mode sorbent (weak anion-exchange and reversed-phase resin), target compounds were chromatographically separated on a C-18 analytical column prior to ESI and MS/MS analysis in multiple reaction monitoring (MRM) mode. Sample preparation and analysis processes were controlled by the addition of a stable isotope-labelled internal standard (ISTD), and LODs between 0.5 and 1.0ng/ml were accomplished for the synthesized model compounds, thus fulfilling the minimum required performance levels (MRPLs)rsoJ for AAS and demonstrating the potential of targeting intact phase II metabolic products in doping controls. Besides facilitating sample preparation and accelerating urine sample analyses, measuring phase II metabolites by LC-MS/MS has been shown to provide a means to accurately quantify steroid conjugates resistant to enzymatic hydrolysis. Kotronoulas and Analysis were measured by LC-ESI-MS/MS in MRM mode. The stationary phase in LC was of C-18 reversed-phase (RP) material, and LODs and limits of quantification (LOQs) were found at 0.2-1 0 and 1-50ng/ml. respectively. Considering the observation that 6-0HA and 6-0HE 3-G-glucuronides might have been underreported in currently employed reference ranges, the authors suggest the re-evaluation of urinary concentrations of these steroid profile parameters.
Combining high-temperature LC employing a porous graphitized carbon column interfaced via an atmospheric pressure photoionization (APPI) source to a high resolution/high accuracy orbitrap analyzer was shown to allow for the sensitive analysis of 57 steroidal compounds from human urine. 1521 Using an approach based on enzymatic hydrolysis followed by liquid-liquid extraction (LLE), target analytes were separated at 90 oc by means of the aforementioned graphitized carbon analytical column (1 00 x 1.0 mm, 3 J.tm particle size). With 0.1% tritluoroacetic acid (solvent A) and acetonitrile/2-propanol (containing 0.1% tritluoroacetic acid, sol· vent B) gradient elution was completed in 20 min, diverting the analytes into the mass spectrometer operated in positive ionization full scan mode (resolution set to 60 000 FWHM). The 57 analytes, amongst which 22 intact (i.e., unmetabolized) steroids were listed, were detected at LODs between 0.1 and 2 ng/ml, providing a sensitivity meeting the stipulated MRPL; however, the identification of a prohibited substance in accordance with the relevant technical document 1531 was not shown, suggesting the use of the presented approach as an initial testing method rather than a confirmatory assay. In addition, the performance of the assay targeting recently identified long-term metabolites of AAS would be of particular interest to outline the fitness-for-purpose of this alternative to established chromatographic-mass spectrometric test methods.
Also utilizing an orthogonal chromatographic system, Novakova alternative for future test methods using GC-APCI-MS/MS; however, the robustness and applicability of the methodology to a broader range of compounds still needs to be established.
Initial testing procedures-metabolism studies and new target anatytes
Identifying best possible target analytes that allow for indicating the misuse of AAS with utmost retrospectivity and specificity has been a cornerstone of anti-doping research for years. Different approaches have been suggested and pursued to accomplish the goal of isolating long-term metabolites of low abundance and/or unexpected composition in a complex matrix such as urine. One option has been the in silica prediction of structures of potential phase I metabolites of steroidal agents and the analysis of elimination studies with particularly sensitive analytical strategies.£ 591 As an example, 32 potential metabolites of metandienone were considered for establishing a test method based on GC with chemical ionization (CI) and QqQ analyzer, where the expected precursorproduct ion pairs for each analyte were derived and predicted by structure similarity to earlier studied compounds.£ 601 The analysis of elimination study urine samples collected up to 31 days enabled the detection of 34 metabolites of mass spectrometrically assigned or confirmed structures. The study corroborated the exceptional retrospectivity accomplished by the long-term metabolite 18-nor17p-hydroxymethyl, 17a-methyl-androst-1,4, 13-trien-3-one, which was traceable using the GC-CI-MS/MS approach for 26-29 days.
An alternative to this ex ante strategy is the use of stable isotope- The observation that the consideration of sulphoconjugated metabolites of AAS significantly contributes to the breadth of initial testing procedures in sports drug testing has been reported further for oxandrolone, danazol, clostebol, metenolone, and drostanolone. Rzeppa and Viet identified steroid sulphates of oxandrolone and danazol in elimination study urine samples, attributed to the sulphoconjugates of 18-nor-17P-hydroxymethyl,17a-methyl-2-oxa5a.-androst-13-en-3-one, ethisterone, 2-hydroxymethylethisterone, 2-hydroxymethyl-1 ,2-dehydroethisterone, and 6P-hydroxy-2-hydroxymethyl-ethisterone, respectively.
1621 For two of these analytes (ethisterone sulphate and 2-hydroxymethylethisterone sulphate), structural confirmation by chemical synthesis was accomplished, which further allowed estimating LODs between 0.5 and 1 ng/ml for these analytes when measured from human urine using a direct injection approach. The steroid sulphoconjugates were chromatographed using a LC system equipped with a C-18 RP column (150 x 2.1 mm, 3 ~tm particle size) that was operated with gradient elution using 0.05% acetic acid (solvent A) and acetonitrile (solvent B). The effluent was directed via positive and negative ESI to a QqQ mass spectrometer measuring diagnostic precursorproduct ion pairs in MRM mode. Balcells eta/. focused on clostebol and its urinary sulphoconjugated metabolites in Caucasians, resulting in the detection of 16 sulphates attributed to clostebol metabolic products. 1631 Several of these metabolites allowed for detection windows of more than 10 days post-administration of different dosages of clostebol, with one metabolite being traceable for up to 31 days by LC-MS/MS. Analyses were conducted on an apparatus consisting of a LC with a C-18 RP column (100 x 2.1 mm, 1.7 llm particle size) enabling the separation of the target analytes by gradient elution. Mass spectral information was generated using ESI and QqQ mass spectrometry employing both positive and negative ionization. The characterization of the metabolite offering the best retrospectivity, i.e. 4~-chloro-5a-androst-3P-ol-17-one sulphate, was based on combined information derived from LC-MS/MS and GC-MS/MS analyses, supporting the assigned structure of the analyte. Similarly, He eta/. studied the elimination of an intramuscular dose of metenolone enanthate and particularly the formation of phase II metabolic products. 1641 A total of 16 glucurono-and sulphoconjugates were identified, including an analyte (assigned to 1-methylen-Sa.-androst-3, 17-dione-2~-sulphate) that was shown to enable a detection window of up to 40 days for the use of the metenolone ester. Urine samples were analyzed either by direct injection or following LLE using LC-ESI-MS/MS. Chromatography was conducted by means of a C -18 RP analytical column (50 x 2.1 mm, 3.5 J.!m particle size) and gradient elution with 10 mM ammonium formate (containing 0.05% formic acid, solvent A for positive ESI), 5 mM ammonium acetate (solvent A for negative E'SI), and acetonitril<> (solvent B)_ High resolution/high accur;;ocy (tandem) mass spectrometry was done using a quadrupole/timeof-flight (Q/TOF) mass analyzer, supporting the rapid identification of the metenolone metabolites' elemental compositions.
Testing and Analysis
Information supporting the structure assignments of the steroid sulphates were obtained after enzymatic hydrolysis of the phase II metabolites using sulphatase from Helix pomatia followed by trimethylsilylation of the resulting asulfates and subsequent GC-MS(!MS) analysis. Analogously, liu eta/. investigated the metabolic fate of intramuscularly administered drostanolone.r 6 sJ Following a single dose of 150 mg of the AAS, 1 0 phase II and one unconjugated metabolite were detected, two of which were suggested to efficiently complement routine doping control analyses. The tentatively identified sulphoconjugate of 2a-methyl-5a-androstane-3a,6~-diol-17-one and the glucuronide of 2a-methyl5a-androstan-3a-ol-17-one were determined up to 24days post-administration, representing potential long-term markers for drostanolone misuse.
Aiming at identifying potential target analytes for uncovering the administration of mepitiostane, Okano et a/. analyzed excretion study urine samples following the oral administration of 1 0 mg of the prohibited AAS. 166 J Mepitiostane acts as prodrug for epitiostanol that, according to earlier in vitro studies, leads to the formation of epitiostanol sulfoxide. Epitiostanol sulfoxide was chemically synthesized and a test method validated based on the enzymatic hydrolysis of urine using ~lucuronidase, LLE of the target analytes, and subsequent LC-MS/MS analysis. Here, chromatography was conducted using a C -8 RP analytical column (50 x 2.1 mm, 1.7 j.lm particle size) and gradient elution (solvent A: 0.1% acetic acid; solvent 8: methanol), and mass spectrometric detection was accomplished · by means of positive ESt and MRM analysis employing a QqQ instrument The assay allowed for LODs of 1.0 and 0.05 ng/ml for epitiostanol and its sulfoxide, respectively, which enabled a detection window in the aforementioned drug administration study of up to 48 h. Employing in vitro and chimeric mouse models, the metabolism of dimethazine was studied by Geldof et a/.r 6 7l using GC-MS/MS and LC-MS/MS with low and high resolution/high accuracy.
Therefore, in vitro study samples as well as urine specimens were liquid-liquid-extracted with and without enzymatic hydrolysis to account for the presence of glucuronic acid conjugates. The extracted analytes were measured by LC-MS(!MS) without further treatment while for GC-MS(!MS) trimethylsilylation was conducted. The GC-MS/MS system was equipped with an ultra-1 capillary column (17m, 0.2 mm inner diameter, 0.11 !!m film thickness) and analytes were separated by means of a temperature gradient. Mass spectrometry was done following El in full scan and MRM mode using quadrupole and QqQ analyzers. In the case of LC-MS/MS, chromatography utilized a C -18 analytical column (1 00 x 2 mm, 3 j.lm particle size), and analytes were ionized by positive ESI prior to analysis by means of either QqQ-based or high resolution/high accuracy orbitrap-based instrument. The formation of six metabolites was observed, which agreed with earlier reported metabolism studies on methasterone, suggesting that monitoring methasterone and its main metabolites will allow for detecting also the misuse of dimethazine. A differentiation whether dimethazine or methasterone was administered might however remain difficult.
The AAS oxymesterone was subjected to in vitro and in vivo metabolism studies in order to complement the metabolic profile of the substance in humans.
168 J Hepatocytes were used to mimic human metabolic reactions, and urine samples were collected up to 30 days after oral administration of 20 mg of the steroid. A total of seven formerly unreported metabolites resulting predominantly from reduction and hydroxylation reaction> wa> de>cribed, with two candidates tentatively identified as 17a-methyi-Sa-
and 17a-methyl-5a-androstane3a,41;_17~-triol. Urine samples were prepared using conventional M. Thevis eta/. strategies based on enzymatic hydrolysis with p-glucuronidase, LLE, and trimethylsilylation prior to GC-MS/MS analysis. The target analytes were separated on an ultra-1 capillary column (25m, 0.2 mm inner diameter, 0.11 j.lm film thickness) before being ionized by El and detected in MRM mode. In the absence of reference material for the newly identified metabolites, their LODs were not determined; however, oxymesterone was measured at concentration levels of 2 ng/ml using the presented GC-MS/MS approach, and the elimination study urine samples were tested positive for the use of oxymesterone by means of the aforementioned metabolites for up to 4 days.
Unexpected elimination profiles of 19-nortestosterone decanoate were observed in a case study with 11 healthy male individuals who received single intramuscular injections of 150 mg of the drug.r 691 Up to 9 month post-administration, urine samples were found to contain 19-norandrosterone, irrespective of differences in genotypes concerning PDE7B1 and UGT2B17. A GC-MS/MS system equipped with an ultra-1 capillary column (17m, 0.2 mm inner diameter, 0.11 ~tm film thickness) and operated in EI-MRM mode was . used to monitor 19-nortestosterone, 19-norandrosterone, and 19-noretiocholanolone, and upon detection of 19-norandrosterone at concentrations higher than the decision limit of 2.5 ng/mlr 701 GC/C/IRMS analysis was conducted in order to confirm the exogenous nature of the analyte.
Characterizing metabolic products and elucidating their biotransformation pathways from the administered drug to renally excreted urinary metabolites have been complex yet important aspects in doping controls. Hence, the utility of ion mobility and collision cross section (CCS) computation in facilitating and contributing to urinary metabolite characterization has been assessed in the case of recently identified N-glucuronides of stanozoloJ.l71l Measuring and computing the CCS values of potential metabolites readily allowed for differentiating stanozolol N-and 0-glucuronides, while unequivocally assigning structures to N1'-and N2'-stanozolol glucuronides was only accomplished after chemical synthesis and nuclear magnetic resonance spectroscopy of the analytes. However, reducing the number of potential structures of steroid metabolites to be synthesized for analyte confirmation purposes is of considerable help and can be supported by the presented approach. Studies contributing to the understanding of routes of steroid metabolism and enzymes involved in respective processes were conducted with dehydrochloromethyltestosterone.r 721 Therefore, three steroidogenic cytochrome P450 enzymes (CYP11A1, CYP11B1, and CYP11B2) were produced, purified, and applied to in vitro studies with dehydrochloromethyltestosterone, which yielded a series of mono-and bishydroxylated species of the AAS. These results indicate that the studied human cytochrome P450 enzymes can participate in AAS biotransformation, which was especially noteworthy regarding the hydroxylation of C-18 of dehydrochloromethyltestosterone, potentially contributing to the formation of the long-term metabolite denoted as 4-chloro-18-nor-17~-hydroxymethyl,17a-methyl-sp-androst-13-en-3a-ol.
Steroid profiling
For decades, steroid profiling has represented a cornerstone of antidoping efforts concerning the detection of AAS misuse in sport and A/etiocholanolone (E), T/EpiT, and 5a-androstane-3a, 17P-diol (Adiol)/5p-androstane-3a, 17p-diol (Bdiol). These are evaluated by means of an adaptive model based on Bayesian inference, which indicates departures of steroid ratios from an athlete's individual reference range and thus possible anti-doping rule violations. In a pilot study aiming at assessing the utility of the steroidal module of the ABP for professional football, the variability of a single marker, the individual T/EpiT ratio, was determined retrospectively for a total of 4195 doping control urine samples collected from 879 male players.£7 41 Acknowledging the limitations of the study, particularly the fact that only one of five parameters of the steroidal module of the ABP was considered and that data were generated prior to the release of applicable operating guidelines, the results were considered promising by the authors, especially for supporting intelligence and target testing in football. In a controlled administration study with 25 male individuals receiving different dosages of intramuscularly injected T enanthate (125, established LCcESI-MS/MS analytical approach, the constituents of a mixed formulation consisting of four T esters (T propionate, T phenylpropionate, T isocaproate, and T decanoate) were determined up to 20 days, while T undecanoate as commonly used in monotherapy was monitored up to day 60 post injection. The relevance of adequate blood sample collection tubes containing sodium fluoride was outlined to avoid ester hydrolysis.
An alternative to measuring (pseudo)endogenous steroidal analytes for detecting the misuse ofT in particular was assessed by Salam in et a/., who monitored the effect of oral and transdermal T applications on a panel of 372 plasma microRNAs (miRNAs).[ 811 The liver-specific miRNA referred to as miR-122 was identified as a potential biomarker forT administrations, which was found to vary considerably on an interindividual basis. Consequently, intra-individual monitoring (the inherent concept of the ABP) was suggested and the search for complementary markers strengthening the contribution of miRNA for future ABP editions was recommended. (THG). trenbolone, and stanozoiol) plus respective phase I metabolites, endogenous androgens (e.g. DHn, progestogens (e.g. progesterone), corticoids (e.g. cortisol), and oestrogens (e.g. oestradiol). Following enzymatic hydrolysis of human urine, all intact AA5 activated the AR assay; phase I metabolites however were largely not recognized and the utility of the AR-based testing approach was found predominantly in its capability of accurately measuring urinary testosterone levels rather than providing a means for monitoring AA5 misuse in sports. The effect of AAS misuse, particularly when conducted over prolonged time periods, on cardiac electrophysiology has led to a discussion on the value of electrocardiogram (KG) interpretations in athletes lately. Controversial results were reported in the past, and Sculthorpe eta/. revisited the suitability of QT interval shortening as a screening tool for identifying AAS misuse from a clinical rather than a doping control analytical perspective.r 831 The analysis of two cohorts including a control group and a population of bodybuilders with a history of 18 (±2) years of AAS use revealed a significant difference in corrected QT intervals; however, specificity and sensitivity of the approach were not considered appropriate to suggest the approach as testing methodology.
Other anabolic agents
Among the class of other anabolic agents, the steroidal selective androgen receptor modulator (SARM) MK-0773 ( Figure 2 ) was studied with regards to its phase I metabolism as investigated by means of different in vitro (bio}transformation methods.£ 841 MK-0773 was first incubated with human liver microsomal preparations, yielding at least 10 mono-oxygenated metabolites as identified by LC-M5(/MS). Upon subjecting MK-0773 also to electrochemistryased metabolism studies, structure confirmation for three products was obtained by means of nuclear magnetic resonance spectroscopy (NMR), with one metabolite being the N-hydroxmethylated analogue to MK-0773. Further, the formation of N-oxides was suggested as supported by retention time, ESI/APCI stability comparison analysis, and product ion mass spectra; however, (electro)chemical synthesis and confirmation of these is still to be completed. New information on elimination kinetics and potential drug-drug interactions of the SARM GTx-024 (Enobosarm, Ostarine, S-22, MK-2866) was presented by Coss et a/. indicating maximum plasma concentrations of the intact drug and its glucuronic acid conjugate of ca. 60 and 100 ng/ml, respectively, reached between 1 and 2 h following an oral dose of 3 mg.rssJ The CYP3A4 inhibitor itraconazole did not affect pharmacokinetic parameters of GTx-024, while the CYP3A4 inducer rifampin reduced maximum plasma concentrations significantly. Conversely, the UGT-inhibitor probenecid increased levels of both GTx-024 and its glucuronide. 
M. Thevis et a/.
Peptide hormones, growth factors, and related substances African trained volunteers, who received 50 IU/kg every two days over a period of 4 weeks. The blood transcriptional profile was found to be significantly altered in 32 transcripts, upregulated during EPO administration periods and affected by 'rebound' phenomena up to 4weeks post administration, leading to the conclusion that these changes in transcriptional signatures can serve as markers for future anti-doping strategies concerning EPO misuse. Figure 3 ) was detected in doping control samples in France as identified by means of LC-MS/MS targeting the intact drug.
Hypoxia-inducible factor stabilizers and activators
1961 Haematological parameters of the convicted athlete were also available, but despite a reported use of the drug over a period of ca. 3 weeks, the ABP score was suspicious only at one occasion, thus stressing the importance of proactively developing test methods that sensitively identify prohibited substances by targeted analyses. Implementing these target compounds appropriate for routine doping controls into existing analytical assays necessitates metabolism studies and, preferably, authentic elimination study urine samples for proof-of-concept. Following in-depth mass spectrometric studies, the PHI GSK1278863 (daprodustat, Figure 3 ) and one of its bishydroxylated metabolites were included into a direct urine injection-based analytical approach using low resolution LC-MS/ MS.[97 1 Using a C-18 RP analytical column (SOx 2.0 mm, 3 J.lm particle size) and gradient elution with 5 mM ammonium acetate (solvent A) and acetonitrile (solvent B), the drug and its main metabolite were identified by negative ESI and MRM at LODs of O.S-1.0ng/ml. In contrast to roxadustat, the post-administration urine sample analyzed in this study revealed only trace amounts of the intact drug. Here, however, at least four different bishydroxlyated species of daprodustat were found at considerable abundance, suggesting the monitoring of metabolites rather than the administered compound for sports drug testing purposes. Besides emerging drugs, arguably obsolete and discontinued compounds have necessitated attention in doping controls. Cobaltous chloride (CoCI 2 ) was identified in solutions observed in the personal surrounding of elite athletes as well as products advertising overtly their erythropoiesis-stimulating properties by proprietary and hence undisclosed ingredients.£ 981 Test methods for the quantification of transition metals such as cobalt are currently not applied to aU human doping control samples, and in contrast to, for example, equine anti-doping regulations} 99 • 1001 no applicable threshold or decision limit has yet been established for cobalt in human blood or urine. Nevertheless, products of identical appearance were found to contain cobalt in mg/ml amounts in one vial and, arguably as a substitute, nickel in another, which suggests an intention of undermining doping control regulations as nickel is not explicitly named as prohibited in sports. 
Growth hormone
The physiological effects of growth hormone (GH), its mediator insulin-like growth factor-! (IGF-1), and GH releasing factors (including GH secretagogues (GHS) and GH releasing peptides (GHRPs)) and their role in the context of anti-doping efforts have been comprehensively reviewed by Nicholls and Holt, where myths and facts of GH are excellently contextualized. 11031 In addition, aspects of analytical approaches including the so-called isoform and biomarker tests were discussed and the potential contribution of longitudinal monitoring of selected biomarkers as part of the ABP were argued. 1351 Complementary to established test methods, the utility of combining biomarkers from transcriptional and (post)translationallevel, namely fibronectin 1 (FN1), RAB31, P-111-NP, and IGF-1 was assessed. 11041 In the course of an administration study with recombinant GH injected at 0.026 mg/kg/day to a total of 10 individuals, a significant increase of mRNA levels of FN1 and RAB31 as well as serum peptide concentrations of FN1 were observed over a period of up to 7 days. The parameters were found to be unaffected by gender and sport discipline and could therefore represent additional sources of information adding to future biomarker assays for targeting the misuse of GH. Of note, the single administration of 100 J.(g of the growth hormone releasing peptide 2 (GHRP-2) did not influence FN1. wileyonlinelibrary.com/journal/dta and Analysis
Corticotrophins, insulin-like growth factor-1 (IGF-1 ), and other growth or releasing factors
Comprehensive mass spectrometry-based approaches for the detection of peptidic drugs and drug candidate in doping controls have been under development for several years with growing success in measuring pharmacologically relevant concentrations of · II . b l"t 11051 both the therapeutiC agents as we as respective meta o 1 es. A new initial testing approach utilizing direct urine injection LC-HRMS in concert with ion mobility was presented, covering 17 different peptidic compounds plus three corresponding metabolites and one non-peptidic GHS. 11061 All analytes exhibited a molecular mass of< 2 kDa and included GHRPs, gonadorelins, a non-erythropoietic EPO receptor agonist, a masking agent, and non-approved substances, all of which were efficiently detected at LODs between 0.05 and 0.5 ng/ml. The analytical setup was based on a sequential use of 2 LC columns with phenylhexyl-and C -18-based stationary phases, operated with gradient elution using 0.1% formic acid (solvent A) and acetonitrile (containing 0.1% formic acid, solvent B). Drift times combined with accurate mass measurements (accomplished by TOF · MS) of singly and/or doubly-charged molecules provided both specificity and sensitivity, enabling fast and robust initial testing of routine doping controls. The entire analytical process was controlled by five internal standards, four of which represented deuterated analogues to target compounds. In consideration of the complexity of doping control matrices such as urine, complementary information as e.g. offered by ion mobility can facilitate decision-making processes.
Alternative drug administration routes such as intranasal applications have been considered for peptidic drugs in various academic and clinical research arenas. 11071 Consequently, elimination properties of four GHRPs (GHRP-1, -2, -6, and hexarelin) and the GHS ipamorelin after intranasal administration were studied by Semenistaya et a/. in order to assess the detectability of the compounds in doping controls as well as to investigate distinct metabolic pathways. 11081 Prior to and up to 48 h after the participants received a single intranasal dose of 5 j.tg/kg of the respective drug (candidate), urine samples were collected and analyzed by nanolC-HRMS as well as low resolution LC-MS/MS. Therefore, specimens were enriched with a stable isotope-labelled ISTD and subjected to weak cation exchange SPE. NanoLC-HRMS was used for analyte characterization, employing a C-18 RP analytical column (150 mm x 75 J.lm, 3.5 J.lm particle size) interfaced via nanospray to a quadrupole/orbitrap-based mass analyzer. Eluents used were 0.1% formic acid (solvent A) and acetonitrile (containing 0.1% formic acid, solvent B). Following chromatographic separation, the analytes were characterized by full scan and MS/MS experiments. Obtained data were subsequently used to establish a routine test method utilizing a normal flow LC equipped with a C-18 RP analytical column (50 x 1 mm, 3.5 J.lm particle size) connected to a QqQ-based MS. Also, here, gradient elution using the same solvents as reported above was employed and target analytes were monitored in MRM mode, allowing for LODs between 50 and 200 pg/mL In accordance to earlier studies with subcutaneous administration routes and/or animal studies, GHRP-1 and GHRP-2 were found to undergo extensive metabolism (suggesting the predominant monitoring of metabolic products), while for GHRP-6, hexarelin and ipamorelin both the intact drugs as well as diagnostic metabolites were considered as suitable target analytf>s.
Intact drugs are also the preferred target analytes for alternative test methods based on receptor binding of GHRPs and GHS. A radio receptor displacement assay utilizing recombinantly engineered
M. Thevis et a!.
cells carrying the GHS receptor 1a was recently assessed as to the impact of fasting/non-fasting states of the tested individual and the concomitantly prevailing ghrelin concentrations, other potent' h ' I" . f d . . [109] tially confounding factors as we as t e assay s 1m1t o ec1s1on. The methodology proved robust against food intake and allowed for identifying the presence of GHRP-2 in urine down to 0.4 ng/ ml, which was denoted as the decision limit rather than LOD due to the natural presence and interindividual variability of urinary GHS activity. Consequently, the assay supports identifying suspicious urine samples in a non-targeted fashion but does not allow confirming an AAF. In contrast to GHRPs and GHS, little information is available on the metabolic fate of growth hormone releasing hormones such as the human growth hormone releasing hormone (GHRH) and its synthetic analogues sermorelin, UC-1293, CJC-1295, and tesamorelin. Hence, Knoop et a/. developed an analytical method targeting particularly GH releasing hormones by means of immuneaffinity purification of plasma samples followed by nanoLC-HRM$.11101 The assay employed Protein NG-coated monoliths embedded in pipette tips for sample extraction, and specimens obtained from animal in vivo studies with sermorelin, UC-1293, CJC-1295, and tesamorelin were analyzed for the intact drugs as well as in silica predicted and in vitro derived metabolites. The analytical setup consisted of a C-18 RP nanoLC column (100 mm x 75 Jlm, 3 11 m particle size) operated with 0.1 o/o formic acid (solvent A) and acetonitrile (containing 0.1 o/o formic acid, solvent B), interfaced via nanoelectrospray to a quadrupole/orbitrap mass analyzer. LODs of 50 pg/ml were accomplished for all intact compounds, enabling the identification of all four drugs/drug candidates in rat plasma samples collected 4 h post-administration. In a simultaneously conducted human administration study with sermorelin, the sermorelin metabolite GHRH 3 _ 29 was detected instead of the intact drug, suggesting an extensive metabolic degradation and, thus, the need to further investigate the metabolism to identify appropriate target analytes for routine doping controls.
Aiming at establishing a LC-HRMS-based multi-analyte test method for peptidic drugs of a molecular mass >2 kDa, Thomas eta/. utilized immunoaffinity purification and LC-HRMS to determine 10 different insulins/insulin metabolites, 4 GHRHs, 3 mechano growth factors (MGFs), IGF-1, long-R 131 -IGF-I, and synacthen from blood and urine. 11111 A mixture of 4 ISTDs (including 3 stable isotope-labelled drug analogues) was used, and urine as well as serum/plasma was extracted by means of drug class-dedicated mono-and polyclonal antibodies captured by Protein A-coated magnetic beads. The same instrumental setup as reported for the aforementioned GHRH study was used, and LODs between 5 and 100 pg/ml and 0.1-2 ng/ml were accomplished for urine and plasma/serum, respectively. In consideration of the growing demand of comprehensive as well as flexible initial testing procedures, the capability of analyzing various peptidic drug classes in one assay appears of particular relevance for routine sports drug testing approaches. A recent example for the need for flexibility was the discovery of the so-called full-length MGF, the potency of which was recently demonstrated justifying the rapid implementation of the analyte into doping controls. 11121 In a randomized and placebo-controlled study, Koch eta/. investigated the effect of 1600 J.tg of inhaled salbutamol on asthmatic as well as non-asthmatic trained cyclists. The amount of 1600 f.tg of salbutamol was administered in one dose prior to a 1 0-km cycling time trial, but despite an increased forced expiratory volume (in 1 s) no significant performance improvement was observed. This outcome supports the rationale of the permitted maximum dose of salbutamol for the specific conditions the test. Further evidence for the relevance of an upper limit of systemic salbutamol use was provided by a study by Hostrup et a/., who assessed the effects of acute and prolonged oral applications of 8 mg of salbutamol on various performance parameters of elite endurance athletes.
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The double-blinded and placebo-controlled drug intervention demonstrated a significant increase in peak power, which led to the conclusion that especially the sprint ability of athletes is improved by the use of prohibited amounts of salbutamol. Urinary concentrations of the ~z-agonists salbutamol and formoterol are determined in sports drug testing to support differentiating intended therapeutic use from doping offences. Therefore, decision limits have been establishedr 701 in consideration of amounts defined as permitted when inhaled, with 1600 J.tg of salbutamol and 54 f.l9 of formoterol (both over a period of 24 h) corresponding to urinary decision limits of 1200 ng/ml and 50 ng/ml, respectively. The question whether these decision limits are appropriate has frequently been challenged using different experimental scenarios, yielding new data for discussion as published in 2015/2016.1n an open-label design study by Pillard et al~ asthmatic cyclists received 3 doses of 200 J.tg of inhaled salbutamol over a period of 12 h on four consecutive days. On day 5, 200 J.tg were administered prior to a 90-min endurance test. Urine samples were collected during rest and after exercise and salbutamol concentrations were determined by LC-MS/MS, revealing peak concentrations of ca. 512 ng/ml (after adjustment to a specific gravity of 1.020). It was therefore concluded that the decision limit for urinary salbutamollevels could be lowered to allow for more stringent doping controls concerning the potential misuse of the ~ragonist in sport.l 1161 As reported above, WADA regulations enforced in 2016 permitted the inhalation of 1600 J.tg of salbutamol per 24 h period, which would include the administration of the allowed dose at one occasion. This situation was mimicked in a study by Haase et a/., where also the effect of dehydration of athletes on urinary salbutamol concentrations following the permitted use of the drug was factored in.l117l Up to 54% of the tested individuals exercising under dehydration conditions exceeded the urinary decision limit of 1200 ng/ml for salbutamol 4 h post-exercise. In accordance to WADA's technical document, no adjustment to a specific gravity of 1.020 was conducted; when adjusting the measured urinary salbutamol concentrations to a specific gravity of 1.020, still 31% of individuals were exceeding the decision limit when inhaling 1600 ILg Of salbutamol and exercising under dehydration conditions. Hence, careful evaluation of AAFs concerning salbutamol was recommended, and a new wording for the use of inhaled salbutamol was introduced into the forthcoming 2017 edition of The use of terbutaline by inhalation is permissible if a therapeutic use exemption (TUE) exists; however, a misuse of supra therapeutic dosages and/or oral administration ofthe drug cannot be excluded.
As demonstrated in a cross-over design pharmacokinetic trial with 4 mg of inhaled or 10 mg of orally administered terbutaline, urine concentrations of the drug do not enable to conclusively differentiate the route of administration. Consequently, the authors recommend establishing urinary thresholds similar to other ~2-agonists such as salbutamol and formoterol. Implementing new long-acting ~2-agonists, namely olodaterol and vilanterol (Figure 4) , into routine doping controls was the subject of a study conducted by Chundela and Grol3e.r 1201 Using LC-MS/MS, both analytes were included into a multi-analyte urine test method consisting of an enzymatic hydrolysis of glucuronic acid conjugates followed by LLE and LC-MS/MS analysis. The LC was equipped with a C-8 RP analytical column (100 x 2.1 mm, 3.5 ~-tm particle size), operated with gradient elution using 2 mM ammonium acetate (containing 0.1% acetic acid and 5% acetonitrile, solvent A) and acetonitrile (containing 5% 2 mM ammonium acetate and 0.1 o/o acetic acid, solvent B). Via positive ESI, the effluent was introduced into a QqQ-based mass spectrometer, and diagnostic precursor/product ion pairs for the intact drugs as well as one metabolite (0-desmethylolodaterol) were monitored in MRM mode. A LOD of 2 pg/ml for was accomplished for both ~ragonists, which was found to be of particular importance given the low concentrations of the drugs found in post-administration samples, where peak concentrations ranged between 0.05 and 0.1 ng/ml.
Hormone and metabolic modulators
Among the class of hormone and metabolic modulators, drugs and drug candidates of considerable diversity are summarized ranging from aromatase inhibitors via agents modifying myostatin function to AMPK agonists, insulins, meldonium, and trimetazidine. A first-in-class analytical assay enabling the detection of myostatin-neutralizing antibodies in doping control serum samples was reported, employing affinity-purification, SDS-PAGE, and subsequent Western blotting as illustrated by means of MY0-029 as model compound.r 12 1l Using both a quality control analyte (MY0-029) and an ISTD (TUBA 1) to account for sample preparation Drug Test. Analysis 2017, 9, 6-29
and Western blotting steps as well as rnyostatin as bait protein, MY0-029 was detected in serum and plasma at concentrations of 0.1 ftg/ml. In consideration of therapeutic plasma levels of myostatin-neutralizing antibodies in the llg/ml range, the assay was found fit-for-purpose and was shown to be specific and robust. Human insulin and 8 of its animal-derived or synthetic analogues were determined in concert with other peptidic drugs as reported above (vide supra) from blood and urine.l 1111 Controlled by the use of 1 0-fold deuterated human insulin as ISTD, urine was concentrated by ultracentrifugation prior to extraction with a monoclonal antibody captured by Protein A-coated magnetic beads. By means of nanolC-HRMS/MS, LODs between 5 and 10 pg/ml were accomplished for insulins and respective metabolites, while the approach adapted for human serum and plasma yielded LODs between 0.1 and 2.0 ng/ml. While the analysis of synthetic and modified insulins has been successfully applied in the past for both doping controls and forensic purposes,l1 221 identifying the misuse of recombinant human insulin has remained an analytical challenge. Aiming at establishing a profile of insulin and its precursor and/or metabolite(s)
indicative for subcutaneous insulin administration, Thomas et a/.
studied the metabolism of insulin caused by epidermal proteases as well as blood samples collected from healthy individuals and insulin-dependent diabetics. 11231 DesB30 human insulin, formerly reported as degradation product found also in human urine, was found to exclusively exist in plasma of individuals having received s.c. injections of human insulin, thus representing a viable marker for surreptitious insulin administrations. following dilution and ultracentrifugation, human insulin and its metabolic products were isolated from plasma using established immunoaffinity purification protocols, and target analytes were measured using nanoLC-HRMS to allow for LODs of 50 pg/ml. Using a pilot study cohort of 10 diabetic and 10 healthy individuals, proof-of-principle data were obtained suggesting the validity of plasma DesS30 human insulin as indicator of insulin use. Larger reference population studies are however suggested for further corroboration. A substantial controversy concerning the inclusion of meldonlum into WADA's Prohibited list of 2016 and the detection of the drug in a great number of doping control urine samples since has resulted in a considerable dispute about the rationale and relevance of meldonium as a doping agent.I ples collected at the European Games held in Baku 2015 were found to contain meldonium and 8320 random sports drug testing samples measured in 2015 in Germany returned 2.2o/o of findings for the drug. The confirmatory test method employed was based on direct urine injection utilizing triply deuterated meldonium as ISTD and hydrophilic interaction liquid chromatography (HILIC) combined with high resolution/high accuracy tandem mass spectrometry. The column used was a HILIC analytical column (100 x 2 mm, 1.8jlm particle size) operated with water (solvent A) and acetonitrile (solvent B), and 200 mM ammonium acetate (containing 0. 15o/o acetic acid, solvent C). Full scan and MS/MS measurements following positive ESI allowed for an LOD of 10 ng/ml and provided unequivocal proof for the presence or absence of the analyte. The considerable number of AAFs registered in 2016 however called into question whether the pharmacokinetic properties of meldonlum needed further investigation, and studies on blood, plasma, and urine collected after controlled administration of meld onium suggested the incorporation of the analyte into erythrocytes and arguably also other bodily tissues.l 1281 A minute whilst
constant release of accumulated meldonium from tissue into the athletes' blood stream and consequently into the urine has since been considered a valid explanation for the unexpected number meldonium findings in doping control samples. The identification of the anti-migraine drug lomerizine as a precursor of trimetazidine ( Figure 5 ) was reported by Okano et a/., alerting athletes, physicians, and predominantly doping control laboratories and anti-doping organizations of the possibility of AAFs concerning trimetazidine caused by the licit use of lomerizine.I 1291 A means to differentiate the origin of the prohibited metabolic modulator was suggested with monitoring intact lomerizine and its diagnostic metabolite M6 (N-dealkylated lomerizine, Figure 5 ) in case of trimetazidine confirmatory analyses. The additional information is considered critical for assigning urinary trimetazidine to the illicit use of the prohibited substance or the permitted use of lomerizine.
Diuretics and other masking agents
Only few studies published in the covered period of 2015/2016 dealt with diuretics and other masking agents in the context of doping controls. Among these studies, glycerol was investigated with regards to its effect on parameters of the haematological module of the ABP when administered intravenously at amounts of 20 g (in 200 ml).l 1301 The infusion of a volume of 200 ml containing 20 g of glycerol resulted in a significant decrease of blood volumedependent parameters such as Hb and HCT as well as the OFFscore; similar changes were however also observed when a volume of 200 ml of electrolyte solution (free of glycerol) was administered, suggesting a limited plasma volume expanding effect of glycerol itself. Urinary concentrations of glycerol were determined by an established GC-MS-based test method and the urinary decision limit of 5.3jlg/ml was exceeded at 1 and 2 h post-administration. The combined analysis of glycerol and mannitol from human urine by means ofLC-MS/MS was reported by Dong eta/.l1 311 Therefore, urine was fortified with stable isotope-labelled glycerol, basifled, and derivatized with benzoyl chloride to yield the benzoyl esters of the target analytes. The derivatized compounds were extracted into n-hexane and injected into an LC-MS/MS system equipped with a C-18 RP analytical column (100 x 2.1 mm, 3.5)lm particle size) interfaced via ESI to a QqQ-based mass spectrometer. The solvents used were 10 mM ammonium formate (pH 3.5 wileyonlinelibrary.com/journal/dta adjusted with formic acid, A) and acetonitrile (B) for the initial testing procedure, while solvent B was exchanged to methanol in case of confirmatory analyses concerning mannitol hexabenzoate, which further necessitated the use of an analytical column using a PFP stationary phase ( 1 SO x 2.1 mm, 2.7 11m particle size) to separate potential isomers of the hexitol. LODs and LOQs ranged from S to 1 SO ng/ml, demonstrating the fitness-for-purpose of the ap-
proach. An alternative method was pursued by Sardela et a/., utilizing a colorimetric initial testing procedure for glycerol followed by a confirmatory analysis by means of GC-MS.£ 1321 Urine was consecutively fortified with sodium periodate, sulfuric acid, and fuchsin to provoke a concentration-dependent pink coloration in the presence of glycerol allowing for the visualization of 0.4 mg/ml of glycerol. Hence, only in case of intense coloration, GC-M5-based quantification was conducted, reducing the need for mass spectrometers in routine screening for glycerol; however, also mannitol and other carbohydrates might trigger colour reactions, resulting in confirmation measurements returning negative test results.
Stimulants
Also in 2016, WADA · s Prohibited List sustained the existence of two groups of stimulants namely non-specified and specified compounds.£ 261 If a stimulant is not explicitly mentioned as being non-specifted, it is automatically considered as specified. Despite the ever-growing plethora of 'designer' psychoactive substances (including psychostimulants)}
-
1351 the detection of such compounds in doping controls has remained at comparably low frequency. Nevertheless, in consideration of the significant health risks associated with these compounds and the enormous number of chemical modifications possible, the indus ion of substances with 'a similar chemical structure or similar biological effect' as defined in WADA's Prohibited list is an appropriate means for covering the most relevant new additions to the market and the identification of novel compounds and characterization of their structures is required in all affected disciplines such as forensic, toxicological, military, and anti~ping sciences.
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Methods to comprehensively test for stimulants (and narcotics) in human urine using LC-MS/MS and GC-MS (following derivatization 11381 demonstrating that modern doping control analytical approaches are readily capable of simultaneously identifying a considerable number of stimulants administered at pharmacologically relevant doses in in-competition doping control samples. Compounds covered in this study also included p-synephrine, an analyte that has been present on WADA's Monitoring Program for several years but was recently shown to have limited (if any) performance-enhancing properties in sprint athletes when administered orally.£ 1391 A particular analytical challenge has been reported with regards to 2-phenylethanamine (phenethylamine, PEA), which is a physiologically relevant substance naturally occurring in humans but also widely sold as dietary supplement. In order to clarify whether athletes have been supplementing PEA. urinary concentrations of the compound proved meaningless; however, monitoring a metabolite characteristic for the oral ingestion of PEA, namely 2-(3-hydroxyphenyl)acetamide sulphate (M1), along with PEA and computing concentration ratios of M1/PEA was found to potentially provide" mean~ to identify the use of PEA.l1 40 1 While the ratio was found to reach values of> 9 in pilot elimination studies, a reference population comprising of 20S doping control samples did not exceed a ratio of 0.9. analysis by GC-MS, elimination curves for the intact drug and one of its metabolites (2-amino-1-phenylbutane) were obtained to support the interpretation of urinary concentrations occurring in the context of AAFs in doping controls. Similarly, the properties of the designer stimulant N,N-dimethyl-2-phenyl-propan-1-amine (NN-DMPPA) as an illicit ingredient in a nutritional supplement were studied.£ 142 1 Also here, GC-MS was used to generate unequivocal analytical data, enabling the quantification of the administered drug in human urine. Following the oral administration of 36S f!g of NN-OMPPA. urinary concentrations of up to 300 ng/ml were monitored within 2-3 h post application, and concentrations above SO ng/ml were still observed after 24 h, outlining the difficulty of assigning the time of drug use to in-vs. out-of-competition periods.
The fact that blood sampling, for example in the form of DBS, could facilitate decision-making processes particularly with regards to findings of compounds prohibited in-competition only was recently supported by a study by Kojima et a/.£ 1431 The analysis of urinary concentrations of ephedrine and methylephedrine in controlled administration studies demonstrated that athletes might test negative (i.e. remain below applicable threshold values) for these substances up to 1 0 h post application but exceed respective threshold levels 12 h after ingestion of the stimulants, affected (amongst others) by urine flow and urinary pH. Conversely, drug blood concentrations as measured from DBS at identical time points as the urine samples yielded robust pharmacokinetics, underlining the considerable potential of DBS as complementary matrix in doping controls. Using a simple two-step extraction protocol for dried blood spots of 20 f!L volume followed by LC -MS/MS on a QqQ mass spectrometer, LOQs of 10 ng/ml were achieved for both ephedrine and methylephedrine. Thereby, peak concentrations were measured between 2 and 8 h post application at 186 (ephedrine) and 122 ng/ml (methylephedrine) after ingestion of 25 mg of each drug. A quantitative bias potentially caused by haematocrit differences was excluded by accurate sampling of blood volumes prior to spotting and use of the entire DBS for analysis. As an alternative to pi petting defined volumes of blood on DBS cards, the technique of volumetric absorptive microsampling was shown to provide reproducible and accurate results. As illustrated with dried urine, plasma, and oral fluid, six model cathinone analogues were detected in 10 f!L specimens sampled by saturation of an absorptive tip, followed by LC-MS/MS analysis.£ precursor/product ion pairs allowed for the sensitive detection of all compounds at lOQs between 0.1 and 1 ng/mL. meeting therapeutic blood concentrations. Also, here, the added value of alternative matrices such as DBS is shown, which might warrant further consideration in anti-doping testing. A more experimental setup based on solid-phase microextraction (SPME) and direct nanoESI-MS/MS analysis was presented, outlining the potential of SPME fibre-based sample extraction and screening analysis of selected narcotics (oxycodone and methadone).r 1471 Sample preparation and measurement was controlled by stable isotope-labelled ISTDs, and overall analysis times were reported with 5 min/sample, applicable to urine and blOod specimens. ln consideration of the partieularly low lOQs (100-500 pg/ml), the approach appears promising for initial testing procedures if required selectivity and sensitivity is proven for a more comprehensive set of compounds relevant for doping controls. The topic of testing for the use and misuse of synthetic glucocorticoids was comprehensively reviewed by Ventura eta/., elaborating especially on the need to differentiate permitted from prohibited routes of corticoid administration.£ 341 An issue not addressed in this article is the need for defined criteria and analytical methods allowing to determine the administration of pseudo-endogenous glucocorticoids. Similar to approaches designed to target. for example the illicit application of testosterone formulations, GC-C-lRMS was utilized to measure the carbon isotopic signature of the target compounds (TCs) cortisol, tetrahydrocortisone, Satetrahydrocortisone, tetrahydrocortisol, and Sa-tetrahydrocortisol for comparison with the endogenous reference compounds (ERC) 11-desoxy-tetrahydrocortisol and pregnanedioiY 481 Sample preparation protocols were adapted from methods used for natural/endogenous androgens and respective metabolites, employing LC fractionation followed by GC-C-IRMS by omitting analyte derivatization.ln a proof-of-concept administration study with cortisol acetate, ~()r 131 C values > 3o/oo were obtained for selected ERC-TC pairs for at least 24h, thus exceeding decision limits proposed for the identification of atypical findings.
1441

Narcotics and glucocorticoids
Manipulation of blood and blood components
The increase of an individual's aerobic capacity by scenarios commonly subsumed under 'blood doping' has a long tradition as therapeutic means in haematology and, on the downside, also in elite sport.r 1491 The performance enhancing effect of autologous blood doping was recently quantified in a setting consisting of two donations of 450 ml of whole blood each, which were cryopreserved as red blood cell concentrates for up to 16 weeks prior to re-infusion. Recreational athletes underv11ent a time-to-exhaustion treadmi!! running tests before and after blood withdrawal as well as 48 h and up to 4 weeks post-infusion. demonstrating a performance in- Using ex vivo-prepared mixtures of human blood and red blood cell concentrates, a panel of 16 loci was tested for the presence of triplets and quadruplets, which would provide evidence for the existence of more than one blood donor for the respective specimen. The assay proved specific for both matrices (whole blood and leukocyte-depleted packed red blood cells), and its sensitivity depended on the percentage of donor blood and the employed threshold chosen for peak assignments. As little as 0.5% of donor blood was identified in 65% of all mixed samples wileyonlinelibrary.com/journal/dta Info Box SO • Phase-1 and -II metabolites of adiponectin receptor agonists (e.g. AdipoRon) were determined and characterized as potential targets for human doping controls.
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• Alternative ionization strategies for multi-analyte initial testing procedures were presented, complementing current GC-MS/MS-and LC-MS/MS-based approaches, expanding analyte coverage, and improving detection limits.
• Studies dedicated to improving the knowledge on urinary phase-! and -II metabolites of AAS resulted in the identification of a series of new metabolic products of established AAS with potential and proven utility in routine doping controls.
• Steroid profiling in serum yields data enabling the detection of transdermal testosterone administrations, irrespective ofthe athlete's UGT2B17 genotype.
• Phase-1 metabolites of the steroidal SARM MK-0773 were identified, complementing and supporting future sports drug testing efforts.
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• EPO-fc can be analyzed by IEF-PAGE when subjected to enzymatic hydrolysis cleaving the Fe moiety between hinge-region and CH2-domain.
• Blood transcriptional profiles suggest detection windows for EPO misuse of up to 4 weeks; additional studies concerning confounding factors appear warranted to assess the assay's utility in doping controls.
• Test methods for HIF stabilizers (e.g. FG-4592, GSK 1278863) were expanded and successfully applied, yielding first AAFs for FG-4592.
• Nickel was found in products advertised as erythropoiesis-stimulating supplement.
• The capability of sub-narcotic xenon administration to stimulate EPO production in human was proven • Serum FN1 and RAB31 were suggested as complementary markers for GH abuse.
• first in vivo data concerning the detection of sermorelin and were presented.
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• Salbutamol use according to WADA-approved limits and routes of administration does not increase endurance performance, but banned usage resulted in increased maximal power and total work. • Decision limits for salbutamol were exceeded when approved conditions (dose, route of administration) were applied during exercise under extreme external circumstances (heat, dehydration, etc.)
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• A first test method for myostatin-neutralizing antibodies for doping controls was developed.
• Meldonium was shown to accumulate in red blood cells.
• The permitted use of the anti-migraine drug lomerizine was shown to form the prohibited drug trimetazidine. 
S6
• p-Synephrine does not exhibit performance enhancing properties in sprint athletes when orally administered.
• Phenylethylamine (PEA} administration can be monitored via the ratio of 2-(3-hydroxyphenyl) acetamide sulfate and PEA.
• Dried blood spots are advantageous in in-competition testing concerning orally administered ephedrine and methylephedrine and the determination of peak plasma/urine concentrations.
S9
• A GC/C/IRMS test method for natural/(pseudo)endogenous corticoids in urine was established.
Ml
• The haematological module of the ABP was found robust against serious fasting conditions and factors such as sport discipline, sex, and season-specific differences; conversely, bolus ingestion of large volumes of water negatively affected the ABP OFF-hr score.
• Plasma hepcidin levels were presented as promising complement to the ABP as a marker for blood transfusion.
• DEHP-free blood bags were found to contain DEHP in traceable amounts.
• Homologous blood transfusion can be uncovered by DNA analyses.
• Perfluorocarbons (PFCs) are readily determined from blood samples using headspace GC-MS/MS M2 • Ingestion of polyethylene glycol (PEG) markers by athletes 30 min prior to doping controls was suggested to allow for unsupervised urine sample collection. wileyonlinelibrary.com/journal/dta when a threshold of 200 relative fluorescence units was applied, indicating a sensitivity competitive to currently employed flow cytometric test methods. Besides homologous and autologous blood transfusions, blood substitutes such as perfluorocarbons (PFCs) are prohibited in sports due to their capability of enhancing the athlete ·s blood oxygen uptake and transport capacity. In a study by Giuliani eta/., gas chromatography utilizing headspace and two consecutive GC columns (1: 624Sil, 30m x 0.2S mm, 1.4 J.lm film thickness; 2: 624, 30m x 0.32 mm, 1.8 J.!m film thickness) was employed to introduce and separate three model PFCs prior to EI-MS/MS conducted on a QqQ-based analyzer. [1 60 J Using 100 J.!L of blood, LODs and LOQs ranging between 1.2 and 9.6 f!g/ml and 12 and 96 )lg/ml, respectively, were accomplished. In consideration of PFC concentrations of 10.000 -70.000 )lg/ml reported for therapeutic use, the assay was found fit-for-purpose, enabling the unequivocal detection of PFCs in doping control blood samples.
Chemical and physical manipulation
To minimize the risk of manipulation during the doping control sampling procedure, urine collection is visually inspected and, thus, an intrusive aa on the athlete. However, the delivery of manipulated urine samples to evade being conviaed of an ADRV has been reported in the past, making control mechanisms inevitable. An alternative to supervised urine sampling was presented by Elbe eta/., who suggest the administration of a mixture of up to four different low molecular mass polyethylene glycols (PEGs, at least SO mg each) 30 min prior to the sample collection. By varying the type and concentration of the PEGs, a diagnostic pattern is obtained that could allow affirming the ingestion of the marker as well as the authenticity of the provided doping control specimen, thus rendering the visual inspection of the sampling process unnecessary.[ 1611 The approach was subject of a pilot study with 91 athletes, and for the majority of athletes the benefits (no supervised sampling) outweighed the disadvantages and concerns (e.g. intolerance). Although no analytical issues were observed during the pilot study, it remains to be shown whether the confounding factors exist that could affect or complicate routine doping control processes. Proving the authenticity of a doping control sample has been essential in various situations in the past, particularly when the suspicion of manipulation is to be verified or falsified. A straight forward approach using DNA typing was presented by Devesse et a/., who developed and evaluated a test method based on a panel of 171oci determined from 1 ml of urine.[
1621 Storage temperature and duration were found to represent critical parameters for successful urinary DNA analyses, and pelleting of samples prior to long-term storage at -20 oc was found beneficial for generating full DNA profiles.
Gene doping
The role and nature of a genetic predisposition for elite athleticism has been discussed and investigated for a number of years, with the 'Athlome' presumably harbouring the information on distinct genetic variants associated with exercise performance, adaptive training responses, and susceptibilities to skeletal muscle injuries. Quantitative nested qPCR assays were used to pre-amplify and detect the target viral plasmid DNA, enabling single copy sensitivity in the presence of SOOng of human genomic DNA.
Proof-of-concept data were obtained by means of an in vivo study with macaques, where the viral vector (containing a promoterless human EPO eDNA sequence) was detected up to 14weeks postinjection in white blood cells.
Conclusion
The number of options to illicitly enhance athletic performance has been constantly growing and, likewise, have the risks for athletes to committing an unintentional anti-doping rule violation been increasing. Hence, anti-doping research has continued focusing on improved test methods enabling the deteaion of prohibited substances and methods of doping, revisiting and updating existing analytical procedures, as well as identifying approaches supporting the differentiation of the use of a prohibited substance from other scenarios that athletes should not be held responsible for. Emphasis of contributions published between October 201S and September 2016 was on anabolic agents resulting in various additional target analytes possibly extending detection windows for routine doping controls. Moreover, studies aiming at identifying new (bio)marker for blood doping practices were reported, and exploiting modern analytical instruments (particularly mass spectrometers) with regards to multi-analyte test methods for peptide-derived drugs in sports drug testing has been the subject of various publications. Key aspects of this Annual Banned-Substance Review are summarized in the Info Box in Figure 6 .
